Ying Chen

Ying Chen

Auto-generated profile, based on publicly available information

Ying Chen

Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, No.288, Tian-Wen Road, Chongqing 40000, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
NZNan Zhang
Nan Zhang
YCYing Chen
Ying Chen
SLShifeng Lou
Shifeng Lou
YSYan Shen
Yan Shen
JDJianchuan Deng
Jianchuan Deng
Objective: Acute myeloid leukemia (AML) is a malignant clonal disorder. Despite enormous progress in its diagnosis and treatment, the mortality rate of AML remains high. The aim of this study was to identify prognostic biomarkers by using the gene expression profile dataset from public database, and to improve the risk-stratification criteria of survival for patients with AML. Materials and methods: The gene expression data and clinical parameter were acquired from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database. A total of 856 differentially expressed genes (DEGs) were obtained from the childhood AML patients classified into first complete remission (CR1) group (n=791) and not CR group (n=249). We performed a series of bioinformatics analysis to screen key genes and pathways, further comprehending these DEGs through Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Results: Six genes (SLC17A7, MSX2, CDC26, MSLN, CTSZ and DEFA3) identified by univariate, Kaplan-Meier survival and multivariate Cox regression analyses were used to develop the prognostic model. Further analysis showed that the survival estimations in the high-risk group had an increased risk of death compared with the low-risk group based on the model. The area under the curve of the receiver operator characteristic curve in the prognostic model for predicting the overall survival was 0.729, confirming good prognostic model. We also performed a nomogram to provide an individual patient with the overall probability, and internal validation in the TARGET cohort. Conclusion: We identified a six-gene prognostic signature for risk-stratifying in patients with childhood AML. The risk classification model can be used to predict CR markers and may assist clinicians in providing realize the individualized treatment in this patient population.

1 July 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
FLFenglian Luo
Fenglian Luo
ZLZhiming Luo
Zhiming Luo
YLYun Luo
Yun Luo
HZHanqing Zeng
Hanqing Zeng
YCYing Chen
Ying Chen
CCChun Cao
Chun Cao